Long-Term Follow-up of Children and Young Adults With B-Cell ALL Treated With CD19 CAR T-Cell Therapy
Autologous CD19 CAR T-cell therapy followed by allogeneic hematopoietic stem cell transplantation can produce prolonged disease control in pediatric patients with relapsed or refractory B-cell ALL...
Patients of Different Races With Early-Onset Colorectal Cancer Exhibit Distinct Genetic Features
Racial differences in genetic mutations were observed among patients with early-onset colorectal cancer...
American Cancer Society Names Karen E. Knudsen, MBA, PhD, as Its Next Chief Executive Officer
Karen E. Knudsen, MBA, PhD, will be the next CEO of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network, starting June 1, 2021...
Anesthesiologist Volume and Adverse Short-Term Outcomes After Complex Surgery for Gastrointestinal Cancer
One study found that higher anesthesiologist volume was associated with reduced risk of short-term adverse postoperative outcomes in patients undergoing surgery for gastrointestinal cancer...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Jame Abraham: Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries
Matthew Zibelman: Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell RCC
Nancy E. Davidson on Cancer and COVID-19: Reflections at 1 Year
Nadine M. Tung on Breast Cancer Susceptibility Genes: Putting the Pieces Together
Chandrakanth Are on the Physician-Patient Relationship
Sponsored Content
Sponsored by Puma Biotechnology
Adjuvant Therapy in HER2-Positive, Hormone Receptor–Positive Breast Cancer
Sponsored by QED Therapeutics
Recent Advances in the Treatment of FGFR-Altered Advanced Cholangiocarcinoma
FDA Approves New Dosing Regimen for Cetuximab in Colorectal Cancer, Head and Neck Cancer
On April 6, the U.S. Food and Drug Administration (FDA) approved a new dosage regimen for cetuximab (Erbitux) of 500 mg/m2 as a 120-minute intravenous infusion every 2 weeks for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck. This...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLC
In the Chinese phase III RATIONALE 307 trial reported in JAMA Oncology, Wang et al found that tislelizumab plus chemotherapy significantly prolonged progression-free survival vs chemotherapy alone in the first-line treatment of patients with advanced squamous non–small cell lung cancer (NSCLC). As...
Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes
For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glenn Family Breast Cancer at the Winship Cancer Institute of Emory University, Atlanta. In the...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Impact of COVID-19 Pandemic on Delivery of Breast Cancer Care in New York
In a single-institution retrospective study focused on a New York City location reported in JCO Oncology Practice, Satish et al found that more than 40% of patients with breast cancer not infected with COVID-19 had a delay or change in care delivery due to the pandemic. Study Details The study...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
